Management of non metastatic castrate resistant prostate cancer is challenging for clinicians due to the heterogeneity of the disease and to the scarce clinical data available in this setting. Recent results obtained with the new generation hormone therapies (NGHT) apalutamide and enzalutamide bring a new perspective for the treatment strategy. The authors present here a systematic review of the treatment options.
Keywords: Castration-resistant; Hormone therapies; Non-metastatic; Prostate cancer; nmCRPC.
Copyright © 2018. Published by Elsevier Ltd.